Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence

Current Opinion in Psychiatry

Volumn 24, Issue 3, 2011, Pages 191-196

  Hall, Wayne ^a,b   Gartner, Coral ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cocaine; drug dependence; drug vaccines; ethics; nicotine; treatment

Indexed keywords

AMFEBUTAMONE; COCAINE; COCAINE VACCINE; DRUG ANTIBODY; NIC 002; NICOTINE; NICOTINE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VACCINE; VARENICLINE;

ABSTINENCE; ADDICTION; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; IMMUNITY; MEDICAL ETHICS; MULTIPLE CYCLE TREATMENT; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

COCAINE-RELATED DISORDERS; HUMANS; POLICY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TOBACCO USE DISORDER; VACCINATION; VACCINES;

EID: 79955114756     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328345922b     Document Type: Article

References (52)

1. Kantak KM. Vaccines against drugs of abuse: a viable treatment option? Drugs 2003; 63:341-352. (Pubitemid 36259522)
2. Kinsey BM, Jackson DC, Orson FM. Antidrug vaccines to treat substance abuse. Immunol Cell Biol 2009; 87:309-314.
3. Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 2007; 16:1775-1783. (Pubitemid 350187391)
4. Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 2009; 92:199-205.
5. Kinsey BM, Kosten TR, Orson FM. Anticocaine vaccine development. Expert Rev Vaccines 2010; 9:1109-1114.
6. Bonese KF, Wainer BH, Fitch FW, et al. Changes in self-administration by a rhesus monkey after morphine immunization. Nature 1974; 252:708-710.
7. Carrera MR, Ashley JA, Wisching P, et al. A second generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 2001; 98:1988-1992. (Pubitemid 32165610)
8. Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2:1129-1132. (Pubitemid 26338633)
9. Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anticocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000; 148:251-262. (Pubitemid 30136732)
10. Sparenborg S, Vocci F, Zubin S. Peripheral cocaine blocking agents: new medications for cocaine dependence. Drug Alcohol Depend 1997; 48:149-151.
11. Lindblom N, de Villiers SH, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behaviour in rats. Respiration 2002; 69:254-260. (Pubitemid 34827841)
12. Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65:191-198. (Pubitemid 30018012)
13. de Villiers SHL, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002; 69:247-253. (Pubitemid 34827840)
14. Ezzati M, Vander Hoorn S, Lopez AD, et al. Comparative quantification of mortality and burden of disease attributable to selected risk factors. In: Lopez AD, Mathers CD, Ezzati M, et al., editors. Global burden of disease and risk factors. New York: The World Bank and Oxford University Press, 2006. pp. 241-396.
15. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008:CD006103.
16. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007:CD000031.
17. Stead L, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008:CD000146.
18. UNODC. World drug report. Vienna: United Nations Office On Drugs and Crime; 2010. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2010.html. [Accessed 22 November 2010]
19. Platt JJ. Cocaine addiction: theory, research and treatment. Cambridge, Massachusetts: Harvard University Press; 1997.
20. Gawin FH, Ellinwood EH. Cocaine and other stimulants: action, abuse and treatment. N Engl J Med 1988; 318:1173-1182.
21. Vasica G, Tennant CC. Cocaine use and cardiovascular complications. Med J Aust 2002; 177:260-262.
22. Torrens M, San L, Peri JM, Olle JM. Cocaine abuse among heroin addicts in Spain. Drug Alcohol Depend 1991; 27:29-34.
23. De Lima MS, Soares BG, Reisser AA, Farrell M. Pharmacological treatment for cocaine dependence: a systematic review. Addiction 2002; 97:931-949.
24. Simpson DD, Joe GW, Broome KM. A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 2002; 59:538-544. (Pubitemid 34602936)
25. Simpson DD, Joe GW, Fletcher BW, et al. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507-514. (Pubitemid 29304643)
26. Kreek MJ. Goals and rationale for pharmacotherapeutic approach in treating cocaine dependence: insights from basic and clinical research. In: Tai B, Ching N, Bridge P, editors. Medication development for the treatment of cocaine dependence: issues in clinical efficacy trials. Rockville, Maryland: NIDA; 1997. pp. 5-35.
27. Fox BS. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 1997; 48:153-158. (Pubitemid 27526021)
28. Cerny EH, Cerny T. Antinicotine abuse vaccines in the pipeline: an update. Expert Opin Investig Drugs 2008; 17:691-696. (Pubitemid 351843613)
29. Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs 2001; 15:505-514. (Pubitemid 32735376)
30. Maastricht University Medical Center. A phase 2B, multicenter, randomized, double-blinded, parallel-arm, study to assess efficacy and safety of 3'-ami-nomethylnicotine-P. Aeruginosa r-exoprotein A conjugate vaccine (NicVAX) or placebo co-administered with varenicline (Champix) as an aid in smoking cessation. Bethesda, Maryland: US National Institutes of Health; 2009. http://clinicaltrials.gov/ct2/show/NCT00995033. [Accessed 22 November 2010]
31. Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58:158-164. (Pubitemid 41008133)
32. Wise RA, Ranaldi R. Cocaine vaccines revisited. Nat Med 1996; 2: 1073-1074. (Pubitemid 26338619)
33. Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20:1196-1204. (Pubitemid 34135957)
34. Martell BA, Orson F, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintenance patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009; 66:1116-1123.
35. National Institute on Drug Abuse (NIDA). A double-blind, randomized, placebo-controlled, multicenter study to assess the clinical efficacy, safety, and immunogenicity of a human cocaine vaccine (TA-CD) in the treatment of cocaine dependence. Bethesda, Maryland: US National Institutes of Health; 2010. http://clinicaltrials.gov/ct2/show/NCT00969878. [Accessed 22 November 2010]
36. Siu EC, Tyndale RF. Nonnicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 2007; 47:541-564.
37. Nabi Biopharmaceuticals. Annual report to shareholders. Rockville, MD: Nabi Biopharmaceuticals; 2009. http://phx.corporate-ir.net/phoenix.zhtml?c= 100445&p=irol-reportsAnnual. [Accessed 25 February 2011]
38. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3:e2547.
39. Novartis. A double blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c. administrations of 100μg NIC002 vaccine in cigarette smokers who are motivated to quit smoking. Bethesda, Maryland: US National Institutes of Health; 2009. http://clinicaltrials.gov/ct2/show/NCT00736047. [Accessed 22 November 2010]
40. Nabi Biopharmaceuticals. Clinical trials NicVAX (nicotine conjugate vaccine). Rockville, Maryland: Nabi Biopharmaceuticals; 2010. http://www.nabi.com/pipeline/clinicaltrials.php#3. [Accessed 22 November 2010]
41. Nabi Biopharmaceuticals. A second phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess efficacy, immunogenicity and safety of 3'-aminomethylnicotine-P. Aeruginosa r-exoprotein a conjugate vaccine (NicVAX) as an aid to smoking cessation. Bethesda, Maryland: US National Institutes of Health; 2010. http://clinicaltrials.gov/ct2/show/study/ NCT01102114. [Accessed 22 November 2010]
42. Nabi Biopharmaceuticals. A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess efficacy, immunogenicity and safety of 3'-aminomethylnicotine-P. Aeruginosa r-exoprotein a conjugate vaccine (NicVAX) as an aid to smoking cessation. Bethesda, Maryland: US National Institutes of Health; 2009. http://clinicaltrials.gov/ct2/show/NCT00836199. [Accessed 22 November 2010]
43. Celtic Pharma Development Services. A phase 2, double-blind, randomized, placebo-controlled, multicenter, dose-ranging study of 100 or 250 mg of TA-NIC to assess the efficacy and safety of the vaccine as an aid to smoking cessation. Bethesda, Maryland: US National Institutes of Health; 2009. http://clinicaltrials.gov/ct2/show/study/NCT00633321. [Accessed 22 November 2010]
44. Cytos Biotechnology. CYT002 Nic Qb: a novel vaccine for nicotine addiction. Zurich: Cytos Biotechnology; 2006. http://www.cytos.com/doc/NicQb- June06-E-fv.pdf. [Accessed 22 November 2010]
45. Hall W. The prospects for immunotherapyinsmoking cessation. Lancet 2002; 360:1089-1091.
46. Degenhardt L, Hall W. The relationship between tobacco use, substance-use disorders and mental health: results from the National Survey of Mental Health and Well Being. Nicotine Tob Res 2001; 3:225-234. (Pubitemid 32821650)
47. Hall W, Lucke J. Legally coerced treatment for drug using offenders: ethical and policy issues. Crime and Justice Bulletin 144. Sydney: New South Wales Attorney General's Department, Bureau of Crime Statistics and Research; 2010. http://www.bocsar.nsw.gov.au/lawlink/bocsar/ll-bocsar.nsf/vwFiles/CJB144. pdf/$file/CJB144.pdf. [Accessed 22 November 2010]
48. Spooner C, Hall W, Mattick RP. An overview of diversion strategies for drug-related offenders. Drug Alcohol Rev 2001; 20:281-294.
49. Porter L, Arif A, Curran WJ. The law and the treatment of drug and alcohol dependent persons: a comparative study of existing legislation. Geneva: World Health Organization; 1986. http://whqlibdoc.who.int/publications/1986/ 9241560932-eng.pdf. [Accessed 22 November 2010]
50. Hall W, Carter L. Ethical implications of using a cocaine vaccine to treat and prevent cocaine dependence. J Med Ethics 2004; 30:337-340. (Pubitemid 39157506)
51. Cohen PJ. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend 1997; 48:167-174. (Pubitemid 27526023)
52. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004; 30:344-345. (Pubitemid 39157508)